Selegiline ? An overview of its role in
โ
Wessel, K. ;Szelenyi, I.
๐
Article
๐
1992
๐
Springer-Verlag
๐
English
โ 389 KB
Selegiline (10 mg per day) selectively inhibits monoamine oxidase type B and thus thwarts the metabolism of dopamine by this enzyme. Selegiline has been used in the therapy of Parkinson's disease since 1986. It enhances the efficacy of levodopa, allows a reduction of the levodopa dose, and improves